The inability to conduct clinical trials amid the pandemic, forced the pharmaceutical industry accelerate the implementation of decentralised trials (DCTs) and virtual trials.

GlobalData conducted a survey to identify the proportion of pre-pandemic DCT use by specific geographies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Only 34% of developers used DCTs before COVID-19 pandemic

Pre-pandemic Decentralised Trials Use by Region

An assessment of the survey results found that only 34% of the respondents were using DCTs before COVID-19 outbreak.

The percentage is the highest in North America, where 41% of the surveyed developers said that they were using virtual trials before the pandemic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was followed by Europe (33%), Asia-Pacific (21%) and Rest of World (17%).

Before the pandemic, the DCTs were generally used for rare diseases to meet subject accrual, paediatric trials and for lower level chronic diseases such as asthma and dermatology.

Such virtual trials also faced more regulatory hurdles.

The analysis is based on responses received from the GlobalData Coronavirus Survey – COVID-19 and Decentralised Clinical Trials fielded between 04 June and 22 June 2020.